The Post-Finasteride Syndrome Foundation, which is listed in the National Institutes of Health’s Genetic and Rare Diseases Information Center, is dedicated to raising funds for scientific and clinical research into post-finasteride syndrome, a condition with no known cure and few, if any, effective treatments. The organization also focuses on generating global awareness of PFS and providing resources for victims and their families.
We understand the devastating and life-altering impact finasteride can have on the sexual, mental and physical health of men. Our primary objective is therefore to work closely with the medical community to spur scientific interest and investigation into PFS, so that underlying biologic mechanisms for persistent finasteride side effects can be found and, hopefully, treatments identified to remedy the condition.
Headquartered in Somerset N.J., the Post-Finasteride Syndrome Foundation is a 501(c)(3) nonprofit corporation established in July 2012.
- Support efforts for achieving medical consensus of post-finasteride syndrome
- Facilitate basic science research to uncover the underlying biologic mechanisms of PFS
- Create awareness among scientists, medical professionals, health care organizations and the media regarding the existence of and need for research into PFS
- Identify potentially effective therapeutic targets and treatment strategies and, hopefully, develop a cure for PFS
Board of Directors
John Santmann, MD, CEO
Dr. John Santmann brings three decades of medical and technology experience to the Post-Finasteride Syndrome Foundation. An emergency department physician by training, he spent two years in residency at Norfolk General Hospital in Norfolk, Va., after completing his internship at Alameda County Medical Center in Oakland, Calif. From 1988 to 1999, he practiced at both community- and academic-based medical centers in Missouri and New Jersey, including the Robert Wood Johnson Medical Center in New Brunswick, NJ. In recent years, Dr. Santmann has worked exclusively in the field of health care information technology. He earned his MD from Washington University School of Medicine in St. Louis and his BA, in biophysics, from the Johns Hopkins University. Dr. Santmann, who was elected CEO of the PFS Foundation in July 2012, resides in New Jersey.
Rosemary E. McGeady, MD, JD, General Counsel
Dr. Rosemary McGeady has had the distinction of practicing law and medicine during her 30-year career, bringing expertise in both disciplines to the Post-Finasteride Syndrome Foundation. Currently an attorney with Levinson Axelrod, she specializes in medical-malpractice law. Prior to joining the firm in 2007, she headed her own medical-legal consulting enterprise, Med Law Consulting. Dr. McGeady, whose father, Paul McGeady, was a noted First Amendment attorney, earned her JD from Seton Hall University and was admitted to the New Jersey Bar in 2005. In 1982, she earned her MD from St. Louis University Medical School, then spent three years in residency at Highland General Hospital in Oakland, Calif., before serving as a staff physician in the Emergency and Cardiology departments of Hampton Veterans Administration Hospital in Hampton, Va. Dr. McGeady later became a partner in the New Brunswick Cardiology Group in New Brunswick, NJ. A Fellow of the College of Legal Medicine and the American College of Cardiology, she was elected general counsel of the PFS Foundation in July 2012. Dr. McGeady resides in New Jersey.
Matthew D. Weintraub, RN, Vice President
Matthew Weintraub RN, BSN, CEN, PHRN, has worked in hospital and pre-hospital acute care medical settings for more than 20 years, and in the health care IT sector for 15 years. He is currently VP of development and operations for a leading health care IT company, where he specializes in federal health care policy initiatives such as the Health Information Technology for Economic and Clinical Health Act (HITECH) and the Health Insurance Portability and Accountability Act (HIPPA). He also remains clinically active, namely as a flight nurse for the Lehigh Valley Hospital and Health Network in Allentown, PA, and is a member of the Emergency Nurses Association, Health Level Seven, National Council for Prescription Drug Programs and Emergency Medical Informatics Association. Mr. Weintraub was elected vice president of the Post-Finasteride Syndrome Foundation in July 2012. He lives with his family in Bethlehem, PA.